Citation Impact
Citing Papers
Temozolomide Preferentially Depletes Cancer Stem Cells in Glioblastoma
2008
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
2013
Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate
2015 StandoutNobel
Randomized Trial of Radiation Therapy Plus Procarbazine, Lomustine, and Vincristine Chemotherapy for Supratentorial Adult Low-Grade Glioma: Initial Results of RTOG 9802
2012
IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group
2010
Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma
2010
A preliminary quantitative proteomic analysis of glioblastoma pseudoprogression
2015
Proteomic dataset for altered glycoprotein expression upon GALNT3 knockdown in ovarian cancer cells
2016 StandoutNobel
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
2008 StandoutNature
Autophagy in cancers including brain tumors: role of MicroRNAs
2020
Astrocytes: biology and pathology
2009 Standout
Response Assessment Criteria for Glioblastoma: Practical Adaptation and Implementation in Clinical Trials of Antiangiogenic Therapy
2013
Efficient multi-scale 3D CNN with fully connected CRF for accurate brain lesion segmentation
2016 Standout
A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07)
2013
IDH1andIDH2Mutations in Gliomas
2009 Standout
A Novel Method for Volumetric MRI Response Assessment of Enhancing Brain Tumors
2011
CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014
2017 Standout
Gene Therapy-Mediated Reprogramming Tumor Infiltrating T Cells Using IL-2 and Inhibiting NF-κB Signaling Improves the Efficacy of Immunotherapy in a Brain Cancer Model
2012 StandoutNobel
Cancer nanomedicine: progress, challenges and opportunities
2016 Standout
Incidence of early pseudo‐progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide
2008
Integrins in cancer: biological implications and therapeutic opportunities
2009 Standout
The future of high-grade glioma: Where we are and where are we going
2015
A survey of MRI-based medical image analysis for brain tumor studies
2013 Standout
Clinical development and potential of photothermal and photodynamic therapies for cancer
2020 Standout
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy
2009
Tumour-infiltrating CD4+ and CD8+ lymphocytes as predictors of clinical outcome in glioma
2014
Glioblastoma and Other Malignant Gliomas
2013 Standout
Malignant astrocytic glioma: genetics, biology, and paths to treatment
2007 Standout
Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131
2015
Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry
2013
Personalized treatment strategies in glioblastoma: MGMT promoter methylation status
2013
A 31-Year-Old Woman With a Transformed Low-grade Glioma
2010
Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme
2010
Autophagy in Brain Tumors: A New Target for Therapeutic Intervention
2011
Biological Functions of Autophagy Genes: A Disease Perspective
2019 Standout
Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
2014 Standout
Controlled drug delivery vehicles for cancer treatment and their performance
2018 Standout
Consensus guidelines for diagnosis, prophylaxis and management of P neumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014
2014
3D Slicer as an image computing platform for the Quantitative Imaging Network
2012 Standout
Cancer stem cells in solid tumours: accumulating evidence and unresolved questions
2008 Standout
The Global DNA Methylation Surrogate LINE-1 Methylation Is Correlated with MGMT Promoter Methylation and Is a Better Prognostic Factor for Glioma
2011
Guidelines on management of low‐grade gliomas: report of an EFNS–EANO* Task Force
2010
MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma
2008
Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas
2010
Anaplastic Oligodendroglioma and Oligoastrocytoma
2007
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
2015
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
2013 Standout
Malignant Gliomas in Adults
2008 Standout
Neurological adverse effects caused by cytotoxic and targeted therapies
2009
MGMT Promoter Methylation and Glioblastoma Prognosis: A Systematic Review and Meta-analysis
2013
Advanced imaging techniques in brain tumors
2009
Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma
2017
Glioblastoma: pathology, molecular mechanisms and markers
2015
Pseudoprogression and pseudoresponse: Challenges in brain tumor imaging
2009
Autophagy modulation as a potential therapeutic target for diverse diseases
2012 Standout
Microtubule-binding agents: a dynamic field of cancer therapeutics
2010 Standout
MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors
2012
A metabolic labeling approach for glycoproteomic analysis reveals altered glycoprotein expression upon GALNT3 knockdown in ovarian cancer cells
2016 StandoutNobel
Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma
2018
Primary brain tumours in adults
2012 Standout
Prognostic and predictive value of epigenetic silencing of MGMT in patients with high grade gliomas: a systematic review and meta-analysis
2011
Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection
2015
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
2016 Standout
Cornerstones of CRISPR–Cas in drug discovery and therapy
2016 StandoutNobel
Therapeutic options for recurrent high-grade glioma in adult patients: Recent advances
2006
High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010
Radiomics: the bridge between medical imaging and personalized medicine
2017 Standout
Honokiol: A Novel Natural Agent for Cancer Prevention and Therapy
2012 Standout
Survival of Patients with Newly Diagnosed Glioblastoma Treated with Radiation and Temozolomide in Research Studies in the United States
2010
Diagnosis and Treatment of High-Grade Astrocytoma
2007
Hypofractionated stereotactic radiation therapy for recurrent glioblastoma: single institutional experience
2013
Bevacizumab and daily temozolomide for recurrent glioblastoma
2011
Management of glioblastoma: State of the art and future directions
2020 Standout
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011–2015
2018 Standout
Efficacy and Tolerability of Temozolomide in an Alternating Weekly Regimen in Patients With Recurrent Glioma
2007
2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis
2016 Standout
CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010
2013 Standout
Therapeutic Application of Noncytotoxic Molecular Targeted Therapy in Gliomas: Growth Factor Receptors and Angiogenesis Inhibitors
2008
The epidemiology of glioma in adults: a "state of the science" review
2014 Standout
Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision
2017 Standout
End Point Assessment in Gliomas: Novel Treatments Limit Usefulness of Classical Macdonald's Criteria
2009
Artificial intelligence in cancer imaging: Clinical challenges and applications
2019 Standout
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014–2018
2021 Standout
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012–2016
2019 Standout
Chemoradiotherapy in Malignant Glioma: Standard of Care and Future Directions
2007
Epidermal Growth Factor Receptor Inhibitors in Neuro-oncology: Hopes and Disappointments
2008
The Versatile Role of microRNA-30a in Human Cancer
2017 Standout
Facile bio-synthesis of gold nanoparticles by using extract of Hibiscus sabdariffa and evaluation of its cytotoxicity against U87 glioblastoma cells under hyperglycemic condition
2015 Standout
MGMT Promoter Methylation Is Prognostic but Not Predictive for Outcome to Adjuvant PCV Chemotherapy in Anaplastic Oligodendroglial Tumors: A Report From EORTC Brain Tumor Group Study 26951
2009
Stereotactic laser ablation of high-grade gliomas
2014
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
2007 Standout
Association Between Hyperglycemia and Survival in Patients With Newly Diagnosed Glioblastoma
2009
Allelic status of 1p and 19q in oligodendrogliomas and glioblastomas: multiplex ligation-dependent probe amplification versus loss of heterozygosity
2009
Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity
2008
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
2010 Standout
Epidemiologic and Molecular Prognostic Review of Glioblastoma
2014 Standout
An extent of resection threshold for newly diagnosed glioblastomas
2011 Standout
Works of V. Blatt being referenced
Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
2007
Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
2009
Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas
2008
Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)
2006
Is protracted low-dose temozolomide feasible in glioma patients?
2006
Correlations Between O6-Methylguanine DNA Methyltransferase Promoter Methylation Status, 1p and 19q Deletions, and Response to Temozolomide in Anaplastic and Recurrent Oligodendroglioma: A Prospective GICNO Study
2006
Second line BCNU plus CPT-11 chemotherapy in recurrent glioblastoma (GBM): Phase II study of GICNO (Italian Neuro-Oncology Group)
2004
MGMT Promoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients
2008